Retour aux projets

13071.1 PFLS-LS

13071.1 PFLS-LS

Résumé

Innovative clinical Phase I trial validation of KLK inhibitor MDPK67b to enter Phase II development in prostate cancer patients

Textes supplémentaires

Abstract

This R&D/Clinical project aims at evaluating the potential effect of a new therapeutic compound, called MDPK67b, for treatment of hormone refractory prostate cancer in a first in man clinical trial in healthy volunteers. The safety and tolerability of MDPK67b in humans will be established to assess its pharmacokinetic profile (PK) in escalating single and repeated doses, and to collect pharmacodynamic (PD) data. It will be important to confirm its biochemical efficacy profile and design rationally a phase II proof of concept trial in patients. Relevant ex vivo tests for determination of drug PD will be developed and used in the clinical trial.

Participants

Christoph Kündig

Wirtschaftspartner

christoph.kundig@med-discovery.com

Med Discovery SA Christoph Kündig Route de la Corniche 4 1066 Epalinges VD CH

Thierry Buclin

Kontaktperson

thierry.buclin@chuv.ch

CHUV Centre Hospitalier Universitaire Va Thierry Buclin Rue du Bugnon 17 1011 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-02-28
Date de fin
2016-09-30
Coûts totaux approuvés
CHF 482878.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%